Total Payments
$416.14
2024 Payments
$286.55
Companies
12
Transactions
20
Medicare Patients
8,330
Medicare Billing
$6.9M
Payment Breakdown by Category
Food & Beverage$337.26 (81.0%)
Education$78.88 (19.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $337.26 | 14 | 81.0% |
| Education | $78.88 | 6 | 19.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $61.52 | 3 | $0 (2024) |
| GlaxoSmithKline, LLC. | $54.83 | 2 | $0 (2024) |
| Acrotech Biopharma LLC | $49.84 | 4 | $0 (2022) |
| ARRAY BIOPHARMA INC | $42.10 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $41.36 | 2 | $0 (2024) |
| Amgen Inc. | $39.61 | 1 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $25.45 | 1 | $0 (2024) |
| Foundation Medicine, Inc. | $24.37 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $24.01 | 1 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.01 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $286.55 | 12 | Celgene Corporation ($61.52) |
| 2023 | $26.34 | 1 | Janssen Biotech, Inc. ($26.34) |
| 2022 | $25.90 | 2 | Acrotech Biopharma LLC ($25.90) |
| 2021 | $23.94 | 2 | Acrotech Biopharma LLC ($23.94) |
| 2019 | $16.75 | 1 | Stemline Therapeutics Inc. ($16.75) |
| 2018 | $36.66 | 2 | Foundation Medicine, Inc. ($24.37) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), RYBREVANT, AKEEGA | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: HORMONE THERAPY | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.13 | General |
| Category: Hematology | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $39.61 | General |
| Category: Bone Health | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.01 | General |
| Category: Oncology | ||||||
| 10/03/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.37 | General |
| Category: Hematology | ||||||
| 08/08/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.02 | General |
| 08/01/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: ONCOLOGY | ||||||
| 05/28/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $26.34 | General |
| 01/27/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2019 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Education | In-kind items and services | $16.75 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 09/06/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 2,359 | 116,884 | $7.1M | $2.4M |
| 2022 | 49 | 2,155 | 99,826 | $4.8M | $1.5M |
| 2021 | 41 | 1,753 | 68,756 | $3.1M | $1.1M |
| 2020 | 50 | 2,063 | 89,108 | $5.0M | $1.8M |
Total Patients
8,330
Total Services
374,574
Medicare Billing
$6.9M
Procedure Codes
193
All Medicare Procedures & Services
193 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 29 | 21,000 | $1.8M | $909,903 | 49.2% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 18,000 | $1.5M | $681,464 | 45.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 5,880 | $264,600 | $109,064 | 41.2% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 12 | 5,700 | $250,800 | $99,783 | 39.8% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 2,625 | $273,000 | $88,338 | 32.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 325 | 801 | $291,564 | $83,902 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 153 | 555 | $397,380 | $69,529 | 17.5% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 17 | 3,140 | $596,600 | $67,588 | 11.3% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 16 | 4,530 | $339,750 | $47,460 | 14.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 12 | 8,320 | $116,480 | $38,955 | 33.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 129 | 253 | $123,717 | $37,649 | 30.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 214 | 440 | $156,640 | $26,647 | 17.0% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 13 | 880 | $102,960 | $25,889 | 25.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 25 | 187 | $59,466 | $13,000 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 135 | 163 | $40,261 | $11,681 | 29.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 15 | 90 | $71,280 | $11,485 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $29,971 | $8,168 | 27.3% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2023 | 33 | 3,400 | $27,200 | $7,718 | 28.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 35 | 117 | $42,120 | $7,175 | 17.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 75 | 455 | $50,050 | $6,575 | 13.1% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 36 | 72 | $40,824 | $5,689 | 13.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 900 | $16,200 | $5,683 | 35.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 51 | 207 | $32,292 | $5,618 | 17.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 21 | 14,280 | $28,560 | $5,513 | 19.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 52 | 271 | $28,726 | $5,144 | 17.9% |
About Janet Wang
Janet Wang is a Hematology & Oncology healthcare provider based in Santa Cruz, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/07/2009. The National Provider Identifier (NPI) number assigned to this provider is 1760629158.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Janet Wang has received a total of $416.14 in payments from pharmaceutical and medical device companies, with $286.55 received in 2024. These payments were reported across 20 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($337.26).
As a Medicare-enrolled provider, Wang has provided services to 8,330 Medicare beneficiaries, totaling 374,574 services with total Medicare billing of $6.9M. Data is available for 4 years (2020–2023), covering 193 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Santa Cruz, CA
- Active Since 01/07/2009
- Last Updated 09/19/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760629158
Products in Payments
- BELEODAQ (Drug) $49.84
- REBLOZYL (Biological) $40.50
- EVENITY (Biological) $39.61
- JEMPERLI (Biological) $32.73
- ORGOVYX (Drug) $25.45
- FOUNDATIONONE (Device) $24.37
- ALUNBRIG (Drug) $24.01
- OPDIVO (Biological) $24.01
- OJJAARA (Drug) $22.10
- BRAFTOVI (Drug) $22.09
- XALKORI (Drug) $20.01
- ELZONRIS (Drug) $16.75
- ERLEADA (Drug) $15.02
- ADCETRIS (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Santa Cruz
Dr. Michael Yen, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $21,862
Hematology & Oncology $21,862
Dr. Amir Tabatabai, M.d, M.D
Hematology & Oncology — Payments: $2,393
Hematology & Oncology $2,393
Rohan Ahluwalia
Hematology & Oncology — Payments: $1,859
Hematology & Oncology $1,859
Glenn Wong, Do, DO
Hematology & Oncology — Payments: $805.72
Hematology & Oncology $805.72
Simranjit Sekhon, M.d, M.D
Hematology & Oncology — Payments: $695.43
Hematology & Oncology $695.43
Raina Ferzoco, M.d, M.D
Hematology & Oncology — Payments: $297.67
Hematology & Oncology $297.67